Inmode Ltd
F:154

Watchlist Manager
Inmode Ltd Logo
Inmode Ltd
F:154
Watchlist
Price: 12.37 EUR -0.04% Market Closed
Market Cap: 943.2m EUR

Inmode Ltd
Investor Relations

InMode Ltd., founded in 2008, has emerged as a dynamic player in the field of minimally invasive aesthetic medical treatments. Born during a period where the health and beauty sectors were experiencing rapid technological innovation, the company quickly carved a niche for itself by addressing a clear market need: the rising demand for non-surgical procedures. At its heart, InMode merges the precision of medical technology with the principles of aesthetic enhancement. Its primary offerings revolve around radio-frequency-based devices that healthcare providers use to achieve results that traditionally required more invasive techniques. This includes skin tightening, fat reduction, and body contouring solutions, all tailored to meet the growing consumer appetite for treatments that carry less downtime and risk compared to conventional surgery.

The company monetizes its expertise by manufacturing and selling these state-of-the-art devices to a diverse group of users, ranging from dermatologists and plastic surgeons to aesthetic practices. InMode's revenue streams are bolstered by not only the direct sale of these devices but also by ongoing client relationships through service agreements and consumable products that are essential for their machine operation. It is a model that ensures continuous engagement with their clients, providing both stability and growth in revenue. By focusing on innovation and efficacy, InMode has successfully captured a significant share of the aesthetic medical market, embodying a business strategy that combines cutting-edge technology with practical solutions to consumer needs.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 5, 2025
AI Summary
Q3 2025

Revenue Drop: Q3 2025 revenue was $93.2 million, down from $130.2 million last year, with the prior period boosted by $31.9 million in preorder sales.

Margins Under Pressure: Gross margin fell to 78% from 82% last year, impacted by tariffs as expected.

Geographic Expansion: New subsidiaries opened in Argentina and Thailand, with international sales rising 10% year-over-year to $40 million.

Consumables Strength: Consumables and service revenues grew 26% year-over-year to $19.9 million, mainly outside the U.S.

Operating Expenses Down: Operating expenses decreased 11% year-over-year to $51.4 million.

2025 Guidance Maintained: Full-year revenue guidance of $365–375 million was reiterated, with no change to margin or EPS guidance.

Leadership Change: Michael Dennison appointed as President of North America to unify management across the region.

Product Pipeline: New lasers and men’s wellness platforms are rolling out, with more launches expected in early 2026.

Key Financials
Revenue
$93.2 million
Consumables and Service Revenue
$19.9 million
International Sales
$40 million
United States Sales
$53.2 million
Gross Margin
78%
Operating Expenses
$51.4 million
Operating Margin
22%
Net Income
$21.8 million
Diluted EPS
$0.34
Cash and Equivalents
$532.3 million
Cash from Operating Activities
$24.5 million
Share-Based Compensation
$2.7 million
Disposable Handpieces Sold
230,000
2025 Revenue Guidance
$365 million to $375 million
2025 Non-GAAP Earnings Per Share Guidance
$1.55 to $1.59
2025 Non-GAAP Income from Operations Guidance
$93 million to $98 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Yair Malca
Chief Financial Officer
No Bio Available
Mr. Alon Yaari
Vice President of Operations
No Bio Available
Dr. Michael Kreindel
CTO & Director
No Bio Available
Ms. Nava Tal-Launer
Chief Information Officer
No Bio Available
Mr. Moshe Mizrahy
CEO & Director
No Bio Available

Contacts

Address
Yokneam
Tavor Building, Sha'ar Yokneam, Pob 533
Contacts
+97249097470.0
inmodemd.com